Maria M. Rubinstein

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 26, 2025

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.

Journal: Journal for immunotherapy of cancer

Published: May 28, 2025

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 22, 2025

Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 05, 2025

Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.

Journal: Gynecologic oncology

Published: January 27, 2025

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 25, 2024

Novel Androgen Receptor Splice Variant 7 in Gynecologic Tumors.

Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists

Published: June 04, 2024

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).

Journal: Gynecologic oncology

Published: November 02, 2023

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.

Journal: Nature medicine

Published: July 12, 2023

Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.

Journal: Gynecologic oncology

Published: May 15, 2023

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.

Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma.

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.

ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.

Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment.

Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment.

Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.

Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

Novel Androgen Receptor Splice Variant 7 in Gynecologic Tumors.

Novel Androgen Receptor Splice Variant 7 in Gynecologic Tumors.

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.

Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.

Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.

Germline drivers of gynecologic carcinosarcomas.

Germline drivers of gynecologic carcinosarcomas.

Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.

Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation.